HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jie-Lena Sun Selected Research

Nateglinide (Starlix)

1/2018Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial.
5/2017Updated risk factors should be used to predict development of diabetes.
4/2017Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
1/2017International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
3/2015Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
12/2013Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
11/2013Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
9/2013Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
3/2013Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
1/2012Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jie-Lena Sun Research Topics

Disease

22Heart Failure
06/2022 - 03/2010
10Glucose Intolerance
01/2018 - 01/2012
5Stroke (Strokes)
12/2020 - 09/2013
4Acute Coronary Syndrome
01/2019 - 01/2008
4Cardiovascular Diseases (Cardiovascular Disease)
01/2018 - 01/2012
4Atrial Fibrillation
11/2013 - 03/2010
3Coronary Artery Disease (Coronary Atherosclerosis)
01/2022 - 03/2010
3Myocardial Infarction
11/2020 - 01/2017
3Hypertension (High Blood Pressure)
04/2014 - 01/2012
2Pneumonia (Pneumonitis)
07/2022 - 12/2020
2Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2020 - 04/2014
2Necrosis
03/2020 - 12/2018
2Coronary Disease (Coronary Heart Disease)
09/2013 - 01/2008
1Bacterial Pneumonia
07/2022
1Disease Progression
01/2021
1Healthcare-Associated Pneumonia
12/2020
1Wounds and Injuries (Trauma)
12/2020
1Muscular Diseases (Myopathy)
03/2020
1Weight Loss (Weight Reduction)
01/2020
1Inflammation (Inflammations)
01/2019
1Melanoma (Melanoma, Malignant)
04/2017
1Skin Neoplasms (Skin Cancer)
04/2017
1Diabetes Mellitus
01/2017
1Venous Thromboembolism
03/2015
1Left Ventricular Dysfunction
12/2014
1Body Weight (Weight, Body)
11/2013
1Type 2 Diabetes Mellitus (MODY)
11/2013
1Hemorrhage
07/2013
1Chronic Obstructive Pulmonary Disease (COPD)
01/2012
1Ventricular Heart Septal Defects (Ventricular Septal Defect)
05/2011
1Tetralogy of Fallot (Fallot Tetralogy)
05/2011
1Atrial Heart Septal Defects (Atrial Septal Defect)
05/2011
1Cardiomyopathies (Cardiomyopathy)
03/2010
1Heart Diseases (Heart Disease)
03/2010

Drug/Important Bio-Agent (IBA)

10Valsartan (Vals)FDA Link
01/2018 - 01/2012
10Nateglinide (Starlix)FDA LinkGeneric
01/2018 - 01/2012
7Brain Natriuretic Peptide (Natrecor)FDA Link
06/2022 - 01/2016
4CreatinineIBA
01/2022 - 01/2012
4DiureticsIBA
01/2021 - 12/2013
3LDL CholesterolIBA
11/2020 - 01/2012
3Biomarkers (Surrogate Marker)IBA
03/2020 - 08/2017
3Type 5 Cyclic Nucleotide PhosphodiesterasesIBA
03/2020 - 12/2018
3Glucose (Dextrose)FDA LinkGeneric
04/2014 - 11/2013
2Oxygen (Dioxygen)IBA
07/2022 - 12/2020
2LiraglutideFDA Link
01/2021 - 01/2020
2Glucagon-Like Peptide 1 (GLP 1)IBA
01/2021 - 01/2020
2Uric Acid (Urate)IBA
12/2020 - 01/2019
2pro-brain natriuretic peptide (1-76)IBA
03/2020 - 01/2020
2C-Reactive ProteinIBA
01/2019 - 12/2018
2HDL CholesterolIBA
04/2014 - 01/2012
2AlbuminsIBA
03/2013 - 01/2012
1Anti-Bacterial Agents (Antibiotics)IBA
07/2022
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2022
1Growth Differentiation Factor 15IBA
01/2021
1LipidsIBA
11/2020
1Cystatin CIBA
01/2020
1SodiumIBA
01/2020
1Ezetimibe (Zetia)FDA Link
01/2019
1Troponin IIBA
12/2018
1TroponinIBA
12/2018
1Interleukin-6 (Interleukin 6)IBA
12/2018
1Tumor Biomarkers (Tumor Markers)IBA
12/2018
1PTX3 proteinIBA
12/2018
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
08/2017
1TicagrelorIBA
08/2017
1Clopidogrel (Plavix)FDA Link
08/2017
1PotassiumIBA
04/2017
1ChloridesIBA
01/2017
1Triglycerides (Triacylglycerol)IBA
04/2014
1Pharmaceutical PreparationsIBA
04/2014
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
12/2013
1CholesterolIBA
01/2012

Therapy/Procedure

5Therapeutics
01/2022 - 03/2010
2Patient Readmission
01/2022 - 01/2020
2Coronary Artery Bypass (Coronary Artery Bypass Surgery)
12/2014 - 07/2013
2Blood Transfusion (Blood Transfusions)
07/2013 - 01/2008
1Mechanical Ventilators (Ventilator)
07/2022
1Palliative Care (Palliative Therapy)
01/2021
1Enteral Nutrition (Feeding, Tube)
12/2020
1Length of Stay
01/2020
1Arterial Switch Operation
05/2011